In 2007, the first multi-target anticancer drug, sorafenib, gained its US-FDA approval for its significant inhibition of cancer progression and angiogenesis through targeting several protein kinases; CD117/c-Kit, platelet-derived growth factor receptor-beta (PDGFR-β), rapidly accelerated fibrosarcoma (Raf), vascular endothelial growth factor receptor (VEGFR)-2, and VEGFR3 [8]. Here, PDGFRB is linked to fibrosarcoma.